Model Parameters Estimating on Lyman–Kutcher–Burman Normal Tissue Complication Probability for Xerostomia on Head and Neck Cancer

Authors: Tsair-Fwu Lee , Hui-Min Ting , Pei-Ju Chao, Jing-Chuan Jiang, Min-Yuan Chao, Wen-Cheng Chen, Long-Chang Chen, Jia-Ming Wu

Abstract:

The purpose of this study is to derive parameters estimating for the Lyman–Kutcher–Burman (LKB) normal tissue complication probability (NTCP) model using analysis of scintigraphy assessments and quality of life (QoL) measurement questionnaires for the parotid gland (xerostomia). In total, 31 patients with head-and-neck (HN) cancer were enrolled. Salivary excretion factor (SEF) and EORTC QLQ-H&N35 questionnaires datasets are used for the NTCP modeling to describe the incidence of grade 4 xerostomia. Assuming that n= 1, NTCP fitted parameters are given as TD50= 43.6 Gy, m= 0.18 in SEF analysis, and as TD50= 44.1 Gy, m= 0.11 in QoL measurements, respectively. SEF and QoL datasets can validate the Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC) guidelines well, resulting in NPV-s of 100% for the both datasets and suggests that the QUANTEC 25/20Gy gland-spared guidelines are suitable for clinical used for the HN cohort to effectively avoid xerostomia.

Keywords: HN, NTCP, SEF, QoL, QUANTEC

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1330927

References:

[1] A. Meirovitz, et al., "Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer," Int J Radiat Oncol Biol Phys, vol. 66, pp. 445-453, 2006.
[2] A. Eisbruch, et al., "Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer," Int J Radiat Oncol Biol Phys, vol. 50, pp. 695-704, 2001.
[3] A. Niemierko and M. Goitein, "Calculation of normal tissue complication probability and dose-volume histogram reduction schemes for tissues with a critical element architecture," Radiother Oncol, vol. 20, pp. 166-176, 1991.
[4] V. Semenenko and X. Li, "Lyman-Kutcher-Burman NTCP model parameters for radiation pneumonitis and xerostomia based on combined analysis of published clinical data," Phys Med Biol, vol. 53, p. 737, 2008.
[5] V. Moiseenko, et al., "Treatment planning constraints to avoid xerostomia in head-and-neck radiotherapy: an independent test of QUANTEC criteria using a prospectively collected dataset," Int J Radiat Oncol Biol Phys, vol. 82, pp. 1108-1114, 2012.
[6] J. O. Deasy, et al., "Radiotherapy dose-volume effects on salivary gland function," Int J Radiat Oncol Biol Phys, vol. 76, pp. S58-S63, 2010.
[7] T. F. Lee, et al., "Dual Arc Volumetric-modulated Arc Radiotherapy (VMAT) of Nasopharyngeal Carcinomas: A Simultaneous Integrated Boost Treatment Plan Comparison with Intensity-modulated Radiotherapies and Single Arc VMAT," Clin Oncol, pp. 196-207, 2011.
[8] J. M. Roesink, et al., "Scintigraphic assessment of early and late parotid gland function after radiotherapy for head-and-neck cancer: a prospective study of dose-volume response relationships," Int J Radiat Oncol Biol Phys, vol. 58, pp. 1451-1460, 2004.
[9] K. Bjordal, et al., "Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35," J Clin Oncol vol. 17, pp. 1008-1008, 1999.
[10] N. K. Aaronson, et al., "The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology," J Natio Cancer Instit, vol. 85, pp. 365-376, 1993.
[11] F. M. Fang, et al., "Multivariate analysis of quality of life outcome for nasopharyngeal carcinoma patients after treatment," Radiother Oncol, vol. 97, pp. 263-269, 2010.
[12] S. W. Leung, et al., "Health-related Quality of life in 640 head and neck cancer survivors after radiotherapy using EORTC QLQ-C30 and QLQ-H&N35 questionnaires," BMC cancer, vol. 11, p. 128, 2011.